51 results about "Therapeutic modalities" patented technology

Apparatus and associated methods relate to management of therapeutic digital assets in a non-medical environment. In an illustrative example, non-medical digital asset(s) (NMDAs) may be evaluated relative to one or more therapeutic modalities. A corresponding therapeutic digital asset (TDA) may, for example, be generated for each therapeutically associated NMDA. The TDA may, for example, be traceably associated with corresponding risks and / or risk mitigations. Each TDA may be associated, for example, with a test profile corresponding to a risk and / or risk mitigation. A TDA may be released into a non-medical digital content delivery environment (DCDE), for example. The TDA may, for example, be monitored in the DCDE to maintain verification and / or validation (VV). A change in the DCDE affecting VV of the TDA may, for example, result in deactivation of the TDA in the DCDE. Various embodiments may advantageously permit VV of selected digital assets in a non-medical environment.

Provided herein are compositions and formulations for alleviating problems associated with glaucomatous neural degeneration and related conditions in an eye comprising the administration of Trabodenoson (eye drops or SR) or MMP based therapeutic modalities. Administration of Trabodenoson results in removing the disease rate limiting root causes associated with neural lineage cell loss in glaucoma and related conditions.

Presented herein are systems and methods that provide for automated analysis of three-dimensional (3D) medical images of a subject in order to automatically identify specific 3D volumes within the 3D images that correspond to specific organs and / or tissue. In certain embodiments, the accurate identification of one or more such volumes can be used to determine quantitative metrics that measure uptake of radiopharmaceuticals in particular organs and / or tissue regions. These uptake metrics can be used to assess disease state in a subject, determine a prognosis for a subject, and / or determine efficacy of a treatment modality.

In some implementations, the system may include one or more processors. In addition, the system may include a non-transitory computer-readable storage medium containing instructions that, when executed by the one or more processors, are configured to cause the system to: store a plurality of data embeddings characterizing and corresponding to an external knowledge base; receive first input data, the first input data characterizing a first patient; receive one or more medical images associated with the first patient and a corresponding prompt requesting a classification of disease characteristics present within the one or more medical images; identify first portions of the knowledge base based on the first input data; and generate, based on at least the first portions of the knowledge base, the one or more medical images, and the corresponding prompt, the classification of disease characteristics and one or more suggested treatment modalities based on the classification of disease characteristics.

The present invention belongs to the technical field of sensorineural hearing. Provided is the use of SPTBN1 as a target in the treatment of GJB2-related sensorineural hearing loss. The use comprises: the construction of a stably transfected cell line, wherein: HEK293T cells are cultured using a DMEM culture medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin in a humidified incubator at 37ºC with 95% air and 5% CO2, and when the cells reach 80%-90% confluence, cell passage is performed; IP-MS analysis, wherein: protein complexes are purified using Protein A / G immunoprecipitation magnetic beads, a portion of the extracted proteins is used as input, and then 2 μg of anti-Cx26 antibody is added to the remaining protein extract, same are gently pipetted and mixed, and incubated on a rotating shaker at 4℃ overnight; immunofluorescence observation of the co-localization of Cx26 and SPTBN1, wherein: a stably transfected cell line expressing WT-Cx26 and Mut-Cx26 is constructed; and co-immunoprecipitation (Co-IP) validation, wherein: a stably transfected cell line expressing WT-Cx26 is constructed. The present invention overcomes the limitations of therapeutic methods, such as the relatively low targeting specificity and short therapeutic time windows associated with full-length protein supplementation via gene therapy, thereby providing new insight into GJB2-related hearing loss, and a new target and a new treatment for same.

Compositions and methods for aptamer-mediated delivery of therapeutic agents. RNA aptamers identified via SELEX specifically bind and are internalized by cardiomyocytes or cardiac fibroblasts, delivering antisense oligonucleotides or other therapeutics intracellularly. This strategy offers a non-viral, targeted approach for treating cardiac diseases and may be extended to other tissues or therapeutic modalities.

The invention discloses an integrated guide control method for a prostate dilation catheter, relates to the technical field of medical treatment, solves the problem of highly integrating two core links of'guide 'and'control' in an operation, and realizes simplification of operation, accuracy of positioning and controllability of mechanical parameters, so that the treatment effect is ensured, and the operation cost is reduced. According to the technical scheme, the method is characterized by comprising the following steps that firstly, preoperative measurement and planning are carried out; 2, a catheter is placed in and initially positioned; 3, integrated guiding and accurate anchoring are carried out; the prostate dilation device has the advantages that the prostate dilation operation is successfully converted from a complex technology which highly depends on experience and equipment to an advanced treatment mode which is standardized, quantitative, minimally invasive and excellent in function protection through unique integrated guide and control design, and revolutionary improvement is brought to multiple dimensions of curative effect, safety, function and efficiency.

Biomarkers are provided that predict whether a subject having a hepatocellular carcinoma is responsive to a therapy comprising sorafenib or a pharmaceutically acceptable salt thereof. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a hepatocellular carcinoma.

Presented herein are systems and methods that provide for automated analysis of three-dimensional (3D) medical images of a subject in order to automatically identify specific 3D volumes within the 3D images that correspond to specific anatomical regions (e.g., organs and / or tissue). Notably, the image analysis approaches described herein are not limited to a single particular organ or portion of the body. Instead, they are robust and widely applicable, providing for consistent, efficient, and accurate detection of anatomical regions, including soft tissue organs, in the entire body. In certain embodiments, the accurate identification of one or more such volumes is used to automatically determine quantitative metrics that represent uptake of radiopharmaceuticals in particular organs and / or tissue regions. These uptake metrics can be used to assess disease state in a subject, determine a prognosis for a subject, and / or determine efficacy of a treatment modality.

The invention belongs to the technical field of medicines, and particularly relates to novel application of polyethylene glycol in preparation of a medicine for treating or reversing pulmonary fibrosis. A new normal form for reversing diseases in a force treatment mode by applying middle-low molecular weight polyethylene glycol (PEG with the molecular weight of 200-3000 Da) to improve extracellular osmotic pressure is put forward and verified for the first time. Through functional verification of cell experiments and animal experiments, the system illustrates that the force treatment activates a mechanical sensitive signal network by inducing alveolar epithelial cell volume compression so as to realize a deep mechanism of EMT (epithelial-mesenchymal transition) molecular cascade reversion. The action path from the physical force to the biological signal provides a brand new theoretical foundation stone for developing a fibrosis treatment strategy based on mechanical microenvironment regulation and control, and PEG300 is a representative preferable embodiment.

A therapeutic device may be configured to improve hand dexterity and strength for an individual requiring rehabilitation of an upper extremity or hand function. The structure may include various graspable features to simulate different hand grasp patterns essential for daily activities. Adjustable weighted components may be modified for specific training needs of the user. The device may allow the simultaneous development of fine motor skills and muscle strength, providing a comprehensive rehabilitation tool. The device may be compact, user-friendly, and may be utilized in various therapeutic settings, including home-based rehabilitation programs. Use of the therapeutic device may streamline a recovery process by integrating multiple therapeutic modalities into a single, efficient training apparatus.

Surgical instruments, methods, and software are presented herein that are configured to actuate an end effector to grasp between the pair of jaws, compress tissue during a tissue relaxation time period in which grasped tissue relaxes between the pair of jaws, monitor a motor parameter of the motor during at least a portion of the tissue relaxation time period, extract a mathematical feature of the motor parameter during at least a portion of the tissue relaxation time period, and determine a treatment modality based at least in part on the mathematical feature.

Methods and systems for recording evoked potentials evoked during electrical stimulation of nervous tissue of a patient are disclosed. These methods and systems can be used in therapeutic regimens, such as spinal cord stimulation (SCS). The disclosed methods and systems allow for reduction or removal of stimulation artifacts in recorded signals. The remainder of the stimulation artifacts may be modeled and subtracted from the recorded signal that includes the artifacts and the neural response contributions.

The present disclosure relates to methods for performing minimally invasive anatomical space access, e.g., minimally invasive subretinal access (MISA), in connection with the delivery of therapeutic modalities to an anatomical space of interest, e.g., the subretinal space, and system components adapted to facilitate such delivery.

The invention discloses application of protoflavin and derivatives thereof in preparation of an METTL7B inhibitor, and belongs to the technical field of medical preparations. The invention aims to solve the technical problem of how to inhibit the enzyme activity of METTL7B. To this end, the present application provides a method for inhibiting the enzymatic activity of methyltransferase METTL7B, the method comprising the step of contacting a substance with methyltransferase METTL7B to inhibit the enzymatic activity of methyltransferase METTL7B, the substance is protoflavin, a stereoisomer thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, a hydrate or solvate of the pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable modifier thereof. The invention discloses application of protoflavin or derivatives thereof in inhibition of activity of methyltransferase METTL7B and application of protoflavin or derivatives thereof in preparation of drugs for treating cancers for the first time, and provides a new research target and a potential new treatment mode for cancers.

An object of a system according to an embodiment is to share treatment policies and cases of orthodontist clinics and allow patients to find an optimal clinic.SOLUTION: A system according to an embodiment includes a data-aggregating unit, a classifying unit, a searching unit, a posting platform unit, and an crowdfunding unit. The data aggregation unit aggregates the existing data of each orthodontic clinic. The classification unit classifies the data aggregated by the data aggregation unit into cases such as age, treatment style, and secular change. The search unit searches for an orthodontist's office optimal for the patient based on the data classified by the classification unit. The posting platform unit allows the user to post the treatment progress. The crowdfunding department collects funds through crowdfunding by patients who give up correction due to high treatment costs.SELECTED DRAWING: Figure 1

Biomarkers are provided that are predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.

A system and method for targeted neurological treatment using brainwave entrainment therapy with passive treatment that allows for targeted treatment of particular areas of the brain, particular neurological functions, particular neurological states, and combinations of areas, functions, and states. The system and method receive gait parameters for an individual and compare those against a database of historical gait data to determine if an onset neurodegenerative condition is present, and applies a brainwave entrainment therapy responsive to the determination of the condition. The system and method receive a neurological assessment identifying areas of the brain or neurological functions to be treated, select one or more treatment modalities and frequencies, select a treatment regimen, and apply brainwave entrainment using a treatment regimen while the subject engages in dual-task activities selected to stimulate the areas of the brain, neurological functions, or neurological states to be treated, enhanced, or altered.

The invention belongs to the technical field of fascia treatment instruments, and particularly relates to a pelvic floor muscle fascia treatment instrument which comprises a computer host and a fascia treatment gun, a pressure induction conduction device and a pressure generation controller are arranged in the fascia treatment gun, and the head of the fascia treatment gun is a cylinder. A pressure sensing diaphragm group and a pressure wave generation contact module are arranged on the surface of the head of the fascia treatment gun, and the pressure sensing diaphragm group comprises a plurality of annular pressure sensing diaphragms. The pelvic floor muscle is treated in a treatment mode of the handheld fascia treatment gun, data statistics is carried out according to pelvic floor muscle feedback pressure, and a treatment scheme is formed; and pressure waves matched with the therapeutic scheme are generated through the pressure wave generation contact module in combination with the therapeutic scheme, so that fascia treatment of pelvic floor muscles is effectively realized.

The present disclosure provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.

Biomarkers are provided that are associated with or predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing vitiligo.

A portable brace assembly for therapeutically supporting an area of a user's body. The assembly generally includes a belt configured to be positioned around the user. One or more inflatable bladders are attached to the belt. One or more additional therapeutic or support modalities configured to be combined with the belt. The additional modalities may be positioned over the inflatable bladders, so that in use the additional modalities are positioned between the inflatable bladders and the user's body. A transdermal medication delivery assembly may be configured to be combined with the first side of the belt as an additional modality.

Provided herein are compositions and formulations for alleviating problems associated with glaucomatous neurodegeneration and eye-related conditions, including administration of trapoxin (eye drops or SR) or MMP-based therapeutic modalities. Administration of trapoxin leads to elimination of the disease rate-limiting underlying cause associated with loss of neural lineage cells in glaucoma and related conditions.

The utility model provides a cover type physical therapy device, and aims to realize tight fit with the surface of a breast by accurately adjusting the angle of an electrode plate, so that the physical therapy effect is improved. The device mainly comprises a shell, an adjusting mechanism and a physical therapy device. The shell comprises a containing cover and an adjusting channel, and the containing cover is used for containing a physiotherapy area and providing enough space for containing physiotherapy devices; the adjusting channel is arranged above the containing cover, and installation and free adjustment of the adjusting mechanism are facilitated. The adjusting mechanism comprises a linkage pressing piece and an angle adjusting structure, the linkage pressing piece can move up and down in the adjusting channel, and the angle adjusting structure is combined to adjust the angle of the electrode slice. The physical therapy device further comprises an infrared emission source and an infrared isolation cover, through the infrared heating effect, the treatment effect is enhanced, and double treatment modes are provided. The device is simple in structure and convenient to operate, the physical therapy effect can be effectively improved, and comfortable and accurate treatment experience is provided.

The present invention relates to a PROTAC compound for targeted degradation of CDK2, a preparation method therefor and a use thereof, and provides a PROTAC compound that is capable of targeted degradation of CDK2. Compared with existing CDK2 inhibitors, the small-molecule compound prepared by the present invention can effectively induce the degradation of CDK2 protein in MCF-7 cells, exhibits good ability to inhibit the proliferation of MCF-7 cells, demonstrates favorable therapeutic effects against breast cancer, and has the potential to become an effective treatment modality for malignant tumors.

Disclosed are blocking peptides and related methods, formulations, and compositions, pertaining to the field of biomedicine. Based on the regulatory mechanism by which the negative regulator TGF-β modulates the transport and degradation of STING, the use of AP3D1 as a drug target for in vitro screening of blocking agents is provided to identify the S9 regulatory site and the R26 regulatory site of AP3D1. Corresponding blocking peptides targeting the S9 regulatory site and the R26 regulatory site, respectively, were synthesized to specifically inhibit AP3D1-mediated inactivation of STING signaling by tumor microenvironment factors, thereby blocking at least one of the S9 regulatory site and the R26 regulatory site and effectively restricting STING transport and degradation. The blocking peptide can synergize with various treatment modalities, including chemotherapy, radiotherapy, PARP inhibitors, and STING agonists, significantly enhancing cGAS-STING signaling activation in tumors during therapy and achieving more potent antitumor efficacy.

Surgical instruments, methods, and software are presented herein that are configured to actuate an end effector to grasp between the pair of jaws, compress tissue during a tissue relaxation time period in which grasped tissue relaxes between the pair of jaws, monitor a motor parameter of the motor during at least a portion of the tissue relaxation time period, extract a mathematical feature of the motor parameter during at least a portion of the tissue relaxation time period, and determine a treatment modality based at least in part on the mathematical feature.

Disclosures herein are directed to methods for classifying and characterizing cancer epithelial cells and analyzing their level of interaction with secondary cell populations in order to identify, modify or otherwise tailor immunotherapy and treatment modalities to a patient. Also disclosed are methods of identifying suitable patient candidates for immunotherapy treatments as well as methods of identifying targets of immunotherapies for the treatment and / or prevention of cancer.

The invention relates to the field of biomarkers, in particular to application of DPP4 activity as a stress individual marker and an immunotherapy synergistic target. It is found that the activity of DPP4 is obviously related to the stress of an individual, and a DPP4 inhibitor can reverse immunosuppression occurring in the individual of the type, so that the benefit of immunotherapy administered by the DPP4 inhibitor is obviously increased. On the basis, an objective stress marker is provided, and clinical screening and diagnosis of related individuals are facilitated; in addition, a treatment mode which can benefit from DPP4 inhibitor treatment is provided for the type of individuals, and accurate locking of treatment crowds in clinic is facilitated.